Business Segment Information (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Jul. 31, 2014		Jul. 31, 2013
Net revenue	$ 1,912		$ 3,020
Sales and marketing costs	(1,034)		(642)
Stock- based compensation expense	(808)		(552)
Personalized Oncology Solutions [Member]
Net revenue	341		622
Direct cost of services	(753)		(744)
Sales and marketing costs	(451)		(333)
Other operating expenses	0		0
Stock- based compensation expense	0	[1]	0	[1]
Segment profit (loss)	(863)		(455)
Translational Oncology Solutions [Member]
Net revenue	1,571		2,398
Direct cost of services	(963)		(870)
Sales and marketing costs	(428)		(246)
Other operating expenses	(1,318)		(389)
Stock- based compensation expense	0	[1]	0	[1]
Segment profit (loss)	(1,138)		893
Unallocated Corporate Overhead [Member]
Net revenue	0		0
Direct cost of services	0		0
Sales and marketing costs	0		0
Other operating expenses	(920)		(652)
Stock- based compensation expense	(808)	[1]	(552)	[1]
Segment profit (loss)	(1,728)		(1,204)
Consolidated [Member]
Net revenue	1,912		3,020
Direct cost of services	(1,716)		(1,614)
Sales and marketing costs	(879)		(579)
Other operating expenses	(2,238)		(1,041)
Stock- based compensation expense	(808)	[1]	(552)	[1]
Segment profit (loss)	$ (3,729)		$ (766)

[1] Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.